Key facts
- HAYA Therapeutics’s last known valuation is $115.5M (Apr 2025).
- It has raised $101.0M; the latest was Later Stage VC ($63.1M) in Apr 2025.
- Notable investors include MassChallenge, Venture Kick, Alexandria Venture Investments, Earlybird Venture Capital, Sofinnova Partners — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for HAYA Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for HAYA Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About HAYA Therapeutics
Operator of a precision therapeutics company intended to discover and develop tissue and cell-selective genomic medicines for fibrotic diseases. The company's therapeutics utilize biopharmaceutical therapy to target a heart-specific regulator of fibrosis and other serious health conditions associated with aging, including cancer, enabling physicians to block myocardial fibrosis and treat heart-related illnesses with efficacy and safety.
- Sector
- Healthcare
- HQ
- Lausanne, Switzerland
- Founded
- 2017
- Employees
- 40
- Website
- hayatx.com/
- Ownership
- Privately Held (backing)
HAYA Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HAYA Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on HAYA Therapeutics in its N-PORT filings yet. We sweep new filings monthly.